Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT06222606
Recruiting Not applicable

Surgery for Thyroid Cancer With or Without Autofluorescence to Prevent Hypoparathyroidism

NCT06222606 · tracked via the Priya Life Science Denmark tracker
Sponsor
Aarhus University Hospital
Phase
Not applicable
Started
2024-01-01
Last updated
2025-10-06

Condition(s) studied

Thyroid Cancer

Investigational drug(s) / intervention(s)

Surgery with autofluorescence

Surgery with autofluorescence: In the experimental group, the surgeon will use the EleVision IR camera system (Medtronic, USA) to visualize parathyroid glands during surgery.

Study summary

The study aims to test if use of autofluorescence imaging (AF) reduces the risk of developing hypoparathyroidism (hypoPT) following surgery for thyroid cancer, either total thyroidectomy (TT) or completion hemithyroidectomy (cHT).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age\>18 years and able to give informed consent. * Suspicion or diagnosis of thyroid cancer. * Planned total thyroidectomy or completion thyroidectomy. * Normocalcemia prior to surgery. Exclusion Criteria: * Planned simultaneous parathyroid surgery. * Treatment with active vitamin D analogues. * eGFR \< 30.

Primary outcome measure(s)

  • Hypoparathyroidism — 6 and 12 months
    Proportion of patients who develop transient or permanent hypoPT requiring medical treatment with active vitamin D. HypoPT is diagnosed and treated according to protocol.

Trial sites (1)

FacilityCityRegionStatus
Aarhus University Hospital Aarhus Denmark Recruiting

More Aarhus University Hospital trials in Denmark

Body Project SMIL: Prevention of Eating Disorders Among Young Women With Psychiatric Illness With the Body Project Starting soon
Assessment of Residual Congestion in Acute Decompensated Heart Failure Recruiting
Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke Recruiting
Progressive Resistance Training for Adults With External Snapping Hip Recruiting
Beyond Survival: Addressing Gynecological and Sexual Health in Women After Radiotherapy for Anal Cancer Recruiting

Other trials for the same condition

Radiofrequency Ablation Versus Hemithyroidectomy for Small Thyroid Cancers Recruiting
Active Surveillance for Bethesda IV Thyroid Nodules Recruiting
Patients With a Single, Small (2 cm or Less) Cancer Nodule in the Thyroid Gland Will be Offered Active Surveillance Initially for 5 Years. In Case of Cancer Growth or Changes in Ultrasonographic Appearance, Further Treatment Will be Offered. Active, not recruiting
Thyroid Nodule Gene Sequencing in a Danish Population Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06222606 on ClinicalTrials.gov ↗ ← All trials in Denmark